Comparison
Argireline vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Metabolic
CAS no.
616204-22-9
2179963-22-7
Molecular weight
888.99 g/mol
4727 g/mol
Half-life
no data
168 h
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Argireline
Argireline is a synthetic hexapeptide whose sequence corresponds to the N-terminus of the SNAP-25 protein. In vitro it has been shown to competitively inhibit SNARE complex formation (necessary for vesicle fusion in neurotransmitter release). Topical application is intended — given very limited skin permeation — to attenuate cholinergic signalling at the neuromuscular endplate. The effect is orders of magnitude weaker than intramuscular botulinum toxin; the clinical translatability of the in-vitro observations to the skin microenvironment is contested.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
2
of which in humans
2
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
2